18 and older, any sex, with Metastatic Colon Adenocarcinoma or Metastatic Rectal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Proportion of Patients Who Have an Actionable Genomic ProfilePrimary· 6 months
This is defined as a patient who received a trial recommendation per the COLOMATE companion trial recommendation form. Will be presented as a point estimate along with a 95% confidence interval (by Wald asymptotic confidence limit).
Group
Value
95% CI
Screening (Genetic Testing)
37.17
30.32 – 44.03
Companion Trial EnrollmentPrimary· 3.5 years
This is defined as a patient who has an actionable genomic profile that enrolls in their recommended companion trial. Will be presented as a point estimate along with a 95% confidence interval (by Wald asymptotic confidence limit).
Group
Value
95% CI
Screening (Genetic Testing)
26.76
16.46 – 37.06
Sponsor's own description
This trial screens patients with colon or rectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) for genetic mutations for recommendation to a molecularly assigned therapy. Identifying gene mutations may help patients enroll onto target companion trials that target these mutations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
· NA
· not yet recruiting
NCT07091617 — Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
· NA
· recruiting
NCT07143487 — Family Communications After Genetic Testing
· NA
· not yet recruiting
NCT03897374 — Strategic Targeting for Optimal Prevention of Cancer
· recruiting
NCT06794567 — Genomic First Testing in Chronic Kidney Disease
· not yet recruiting
Other recruiting trials for Metastatic Colon Adenocarcinoma
Currently open trials in the same condition.
NCT05627635 — FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite
· Phase 1, PHASE2
· active not recruiting
NCT05308446 — Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer T
· Phase 2
· active not recruiting
NCT04616183 — LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorec
· Phase 1, PHASE2
· active not recruiting
NCT04599140 — SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC
· Phase 1, PHASE2
· active not recruiting
NCT03992456 — Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal
· Phase 2
· active not recruiting
Other Academic and Community Cancer Research United trials
Trials by the same sponsor.
NCT06160206 — Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
· Phase 2
· recruiting
NCT06238648 — Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
· Phase 2
· recruiting
NCT05910801 — Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
· Phase 2
· recruiting
NCT05356897 — Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molec
· Phase 2
· withdrawn
NCT05194293 — Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
· Phase 2
· active not recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Academic and Community Cancer Research United
Last refreshed: 29 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03765736.